IBO
Price
$0.46
Change
+$0.02 (+4.55%)
Updated
Sep 11 closing price
Capitalization
49.62M
Intraday BUY SELL Signals
LPCN
Price
$2.27
Change
+$0.02 (+0.89%)
Updated
Sep 11 closing price
Capitalization
18.63M
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IBO vs LPCN

IBO vs LPCN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IBO vs. LPCN commentary
Sep 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBO is a StrongBuy and LPCN is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBO($49.6M) has a higher market cap than LPCN($18.6M). IBO YTD gains are higher at: -8.871 vs. LPCN (-71.731). IBO has higher annual earnings (EBITDA): -397K vs. LPCN (-12.51M). LPCN has more cash in the bank: 23.3M vs. IBO (10K). LPCN has less debt than IBO: LPCN (1.48M) vs IBO (22.9M). LPCN has higher revenues than IBO: LPCN (1.57M) vs IBO (35K).
IBOLPCNIBO / LPCN
Capitalization49.6M18.6M267%
EBITDA-397K-12.51M3%
Gain YTD-8.871-71.73112%
P/E Ratio0.52N/A-
Revenue35K1.57M2%
Total Cash10K23.3M0%
Total Debt22.9M1.48M1,545%
FUNDAMENTALS RATINGS
IBO vs LPCN: Fundamental Ratings
IBO
LPCN
OUTLOOK RATING
1..100
9839
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
898
PRICE GROWTH RATING
1..100
6263
P/E GROWTH RATING
1..100
3496
SEASONALITY SCORE
1..100
3050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LPCN's Valuation (58) in the Pharmaceuticals Other industry is in the same range as IBO (71) in the null industry. This means that LPCN’s stock grew similarly to IBO’s over the last 12 months.

LPCN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as IBO (100) in the null industry. This means that LPCN’s stock grew similarly to IBO’s over the last 12 months.

IBO's SMR Rating (8) in the null industry is significantly better than the same rating for LPCN (98) in the Pharmaceuticals Other industry. This means that IBO’s stock grew significantly faster than LPCN’s over the last 12 months.

IBO's Price Growth Rating (62) in the null industry is in the same range as LPCN (63) in the Pharmaceuticals Other industry. This means that IBO’s stock grew similarly to LPCN’s over the last 12 months.

IBO's P/E Growth Rating (34) in the null industry is somewhat better than the same rating for LPCN (96) in the Pharmaceuticals Other industry. This means that IBO’s stock grew somewhat faster than LPCN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBOLPCN
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
N/A
Bullish Trend 5 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
16%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 13 days ago
78%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
COMPARISON
Comparison
Sep 13, 2026
Stock price -- (IBO: $0.46 vs. LPCN: $2.27)
Brand notoriety: IBO and LPCN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBO: 199% vs. LPCN: 27%
Market capitalization -- IBO: $49.62M vs. LPCN: $18.63M
IBO [@Biotechnology] is valued at $49.62M. LPCN’s [@Biotechnology] market capitalization is $18.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBO’s FA Score shows that 1 FA rating(s) are green while LPCN’s FA Score has 0 green FA rating(s).

  • IBO’s FA Score: 1 green, 4 red.
  • LPCN’s FA Score: 0 green, 5 red.
According to our system of comparison, IBO is a better buy in the long-term than LPCN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBO’s TA Score shows that 6 TA indicator(s) are bullish while LPCN’s TA Score has 6 bullish TA indicator(s).

  • IBO’s TA Score: 6 bullish, 3 bearish.
  • LPCN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, IBO is a better buy in the short-term than LPCN.

Price Growth

IBO (@Biotechnology) experienced а -14.78% price change this week, while LPCN (@Biotechnology) price change was -7.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

LPCN is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IBO
Daily Signal:
Gain/Loss:
LPCN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MYND0.380.01
+2.70%
Myndai
CMI556.756.72
+1.22%
Cummins
NPKI13.260.07
+0.53%
NPK International Inc
CPA129.150.59
+0.46%
Copa Holdings SA
AREC2.14-0.05
-2.28%
American Resources Corp

IBO and

Correlation & Price change

A.I.dvisor tells us that IBO and PCSA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IBO and PCSA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBO
1D Price
Change %
IBO100%
+4.35%
PCSA - IBO
32%
Poorly correlated
+12.43%
INDP - IBO
27%
Poorly correlated
+8.20%
LPCN - IBO
27%
Poorly correlated
+0.89%
AZTR - IBO
26%
Poorly correlated
-1.11%
LIMN - IBO
24%
Poorly correlated
-4.41%
More

LPCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LPCN has been loosely correlated with SPRY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if LPCN jumps, then SPRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LPCN
1D Price
Change %
LPCN100%
+0.89%
SPRY - LPCN
63%
Loosely correlated
-5.93%
HYFT - LPCN
43%
Loosely correlated
-1.14%
ELAB - LPCN
42%
Loosely correlated
-1.74%
INO - LPCN
41%
Loosely correlated
-2.34%
ZNTL - LPCN
36%
Loosely correlated
-2.23%
More